Inozyme Pharma Stock Today
| INZY Stock | USD 1.42 0.10 6.58% |
Performance0 of 100
| Odds Of DistressOver 81
|
Inozyme Pharma is trading at 1.42 as of the 30th of January 2025; that is 6.58 percent decrease since the beginning of the trading day. The stock's open price was 1.52. Inozyme Pharma has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 31st of December 2024 and ending today, the 30th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 24th of July 2020 | Category Healthcare | Classification Health Care |
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts. The company has 64.24 M outstanding shares of which 3.85 M shares are currently shorted by private and institutional investors with about 5.41 trading days to cover. More on Inozyme Pharma
Moving together with Inozyme Stock
Moving against Inozyme Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Inozyme Stock Highlights
| CEO Chairman | Douglas Treco | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsInozyme Pharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Inozyme Pharma's financial leverage. It provides some insight into what part of Inozyme Pharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Inozyme Pharma (INZY) is traded on NASDAQ Exchange in USA. It is located in 321 Summer Street, Boston, MA, United States, 02210 and employs 59 people. Inozyme Pharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 91.22 M. Inozyme Pharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 64.24 M outstanding shares of which 3.85 M shares are currently shorted by private and institutional investors with about 5.41 trading days to cover.
Inozyme Pharma currently holds about 151.48 M in cash with (70.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.77, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Inozyme Pharma Probability Of Bankruptcy
Ownership AllocationInozyme Pharma has a total of 64.24 Million outstanding shares. The majority of Inozyme Pharma outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Inozyme Pharma to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Inozyme Pharma. Please pay attention to any change in the institutional holdings of Inozyme Pharma as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Inozyme Ownership Details
Inozyme Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Millennium Management Llc | 2024-09-30 | 1.7 M | |
| Samsara Biocapital, Llc | 2024-09-30 | 1.6 M | |
| Saturn V Capital Management Llc | 2024-09-30 | 1.4 M | |
| Sphera Funds Management Ltd. | 2024-09-30 | 1.2 M | |
| Geode Capital Management, Llc | 2024-09-30 | 1.2 M | |
| Blue Owl Capital Holdings Lp | 2024-09-30 | 1.1 M | |
| State Street Corp | 2024-09-30 | 1.1 M | |
| Woodline Partners Lp | 2024-09-30 | 1 M | |
| Goldman Sachs Group Inc | 2024-09-30 | 447.3 K | |
| Adage Capital Partners Gp Llc | 2024-09-30 | 5.7 M | |
| Pivotal Bioventure Partners Investment Advisor Llc | 2024-09-30 | 4.5 M |
Inozyme Pharma Historical Income Statement
Inozyme Stock Against Markets
Inozyme Pharma Corporate Management
| Henric Bjarke | VP COO | Profile | |
| Gayle Gironda | Senior Officer | Profile | |
| MA MS | Advisor Board | Profile | |
| MSc MBA | President, CoFounder | Profile | |
| MS MBA | CFO Officer | Profile |
Additional Tools for Inozyme Stock Analysis
When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.